FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PANK1-ABCC2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PANK1-ABCC2
FusionPDB ID: 62538
FusionGDB2.0 ID: 62538
HgeneTgene
Gene symbol

PANK1

ABCC2

Gene ID

53354

1244

Gene namepantothenate kinase 1ATP binding cassette subfamily C member 2
SynonymsPANKABC30|CMOAT|DJS|MRP2|cMRP
Cytomap

10q23.31

10q24.2

Type of geneprotein-codingprotein-coding
Descriptionpantothenate kinase 1pantothenic acid kinase 1canalicular multispecific organic anion transporter 1ATP-binding cassette, sub-family C (CFTR/MRP), member 2canalicular multidrug resistance proteinmultidrug resistance-associated protein 2
Modification date2020031320200329
UniProtAcc.

Q92887

Main function of 5'-partner protein: FUNCTION: ATP-dependent transporter of the ATP-binding cassette (ABC) family that binds and hydrolyzes ATP to enable active transport of various substrates including many drugs, toxicants and endogenous compound across cell membranes. Transports a wide variety of conjugated organic anions such as sulfate-, glucuronide- and glutathione (GSH)-conjugates of endo- and xenobiotics substrates (PubMed:10220572, PubMed:10421658, PubMed:11500505, PubMed:16332456). Mediates hepatobiliary excretion of mono- and bis-glucuronidated bilirubin molecules and therefore play an important role in bilirubin detoxification (PubMed:10421658). Mediates also hepatobiliary excretion of others glucuronide conjugates such as 17beta-estradiol 17-glucosiduronic acid and leukotriene C4 (PubMed:11500505). Transports sulfated bile salt such as taurolithocholate sulfate (PubMed:16332456). Transport various anticancer drugs, such as anthracycline, vinca alkaloid and methotrexate and HIV-drugs such as protease inhibitors (PubMed:10220572, PubMed:11500505, PubMed:12441801). Confers resistance to several anti-cancer drugs including cisplatin, doxorubicin, epirubicin, methotrexate, etoposide and vincristine (PubMed:10220572, PubMed:11500505). {ECO:0000269|PubMed:10220572, ECO:0000269|PubMed:10421658, ECO:0000269|PubMed:11500505, ECO:0000269|PubMed:12441801, ECO:0000269|PubMed:16332456}.
Ensembl transtripts involved in fusion geneENST idsENST00000307534, ENST00000322191, 
ENST00000342512, ENST00000371774, 
ENST00000488482, 
ENST00000370434, 
ENST00000496621, ENST00000370449, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score5 X 3 X 5=754 X 4 X 3=48
# samples 54
** MAII scorelog2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/48*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PANK1 [Title/Abstract] AND ABCC2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PANK1 [Title/Abstract] AND ABCC2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PANK1(91404357)-ABCC2(101606718), # samples:1
Anticipated loss of major functional domain due to fusion event.PANK1-ABCC2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PANK1-ABCC2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:91404357/chr10:101606718)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PANK1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ABCC2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000307534PANK1chr1091404357-ENST00000370449ABCC2chr10101606718+1912859156923255

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000307534ENST00000370449PANK1chr1091404357-ABCC2chr10101606718+0.27705790.7229421

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PANK1-ABCC2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PANK1chr1091404357ABCC2chr10101606718859235RRRMDSGRKNRPRPHPVLWKPEDESR

Top

Potential FusionNeoAntigen Information of PANK1-ABCC2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PANK1-ABCC2_91404357_101606718.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:10RPRPHPVL0.99990.87321018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:02RPRPHPVL0.99990.85891018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:05RPRPHPVL0.99990.70621018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B08:09RPRPHPVL0.99780.78481018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:01NRPRPHPV0.99630.9202917
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:02NRPRPHPV0.99630.9202917
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:02RPRPHPVL0.99070.94471018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:01RPRPHPVL0.99070.94471018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B53:01PRPHPVLW0.8610.51721119
PANK1-ABCC2chr1091404357chr10101606718859HLA-B81:01RPRPHPVL0.81380.69371018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:02RPRPHPVLW0.99690.72561019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:05RPRPHPVLW0.99520.69891019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:01NRPRPHPVL0.99460.936918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:02NRPRPHPVL0.99460.936918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:01NRPRPHPVL0.9940.9574918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:24NRPRPHPVL0.99390.5055918
PANK1-ABCC2chr1091404357chr10101606718859HLA-A30:08KNRPRPHPV0.99380.6907817
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:06NRPRPHPVL0.99340.9146918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B38:02NRPRPHPVL0.9810.9779918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B38:01NRPRPHPVL0.97080.9757918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B57:01RPRPHPVLW0.96460.9171019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:10NRPRPHPVL0.95190.5136918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B58:02RPRPHPVLW0.9140.92451019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:37NRPRPHPVL0.86270.6055918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B58:01RPRPHPVLW0.79350.89971019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:18NRPRPHPVL0.78160.7152918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B57:03RPRPHPVLW0.76090.9751019
PANK1-ABCC2chr1091404357chr10101606718859HLA-A31:08RPRPHPVLW0.75460.81781019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:05RPRPHPVLW0.68010.5861019
PANK1-ABCC2chr1091404357chr10101606718859HLA-A32:13RPRPHPVLW0.65610.94061019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:08RPRPHPVLW0.50830.70571019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:10NRPRPHPVL0.46450.6587918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B55:01RPRPHPVLW0.14170.59151019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B82:01RPRPHPVLW0.08460.70161019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B81:01RPRPHPVLW0.03440.76911019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B58:02KNRPRPHPVLW0.99970.7436819
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:12RPRPHPVL0.99970.90881018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B42:02RPRPHPVL0.99930.5181018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:03RPRPHPVL0.99880.93441018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B42:01RPRPHPVL0.99870.51131018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:04RPRPHPVL0.99850.81971018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B56:04RPRPHPVL0.92650.59761018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B78:01RPRPHPVL0.87050.57531018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:10RPRPHPVL0.80510.96851018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:09NRPRPHPVL0.99520.8379918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:95NRPRPHPVL0.99280.744918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:12NRPRPHPVL0.99170.9605918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:05NRPRPHPVL0.99030.9546918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:27NRPRPHPVL0.98730.9478918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:29NRPRPHPVL0.98580.9415918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:13NRPRPHPVL0.98230.9223918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:05NRPRPHPVL0.97920.9489918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:46NRPRPHPVL0.94030.9099918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B54:01RPHPVLWKP0.90210.61521221
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:10NRPRPHPVL0.85610.9557918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:04RPRPHPVLW0.85320.7481019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:80NRPRPHPVL0.84880.959918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:67NRPRPHPVL0.84880.959918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:12RPRPHPVLW0.84430.79341019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:19NRPRPHPVL0.84040.765918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B14:03NRPRPHPVL0.82830.9153918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B73:01NRPRPHPVL0.73240.8471918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B42:01RPRPHPVLW0.42710.51411019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B42:02RPRPHPVLW0.40040.52261019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C12:16NRPRPHPVL0.19850.9647918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B44:08RPRPHPVLW0.14580.72651019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:05RPRPHPVLW0.09820.89331019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:19RPRPHPVLW0.09640.81741019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B51:07RPRPHPVLW0.09140.86651019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:95RPRPHPVLW0.06120.65491019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:19NRPRPHPVLW0.90820.7354919
PANK1-ABCC2chr1091404357chr10101606718859HLA-B48:05RPRPHPVL0.99990.65571018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:22RPRPHPVL0.99990.85891018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:09RPRPHPVL0.99990.84961018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B55:04RPRPHPVL0.98840.56281018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B08:12RPRPHPVL0.97580.77811018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B56:02RPRPHPVL0.92650.59761018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B53:02PRPHPVLW0.91450.571119
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:26RPRPHPVL0.9080.73511018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B67:01RPRPHPVL0.88590.96191018
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:09RPRPHPVLW0.99750.71581019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B27:06NRPRPHPVL0.99690.7566918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:22RPRPHPVLW0.99690.72561019
PANK1-ABCC2chr1091404357chr10101606718859HLA-A30:01KNRPRPHPV0.99430.759817
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:31NRPRPHPVL0.99410.9581918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:01NRPRPHPVL0.99290.7175918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:17NRPRPHPVL0.98110.9701918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B38:05NRPRPHPVL0.97080.9757918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B57:10RPRPHPVLW0.96460.9171019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:22NRPRPHPVL0.88980.7973918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C06:08NRPRPHPVL0.88890.9857918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:02NRPRPHPVL0.84880.959918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:04NRPRPHPVL0.83470.9404918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B58:06RPRPHPVLW0.83160.92881019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B57:04RPRPHPVLW0.82560.72741019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:09NRPRPHPVL0.80530.6187918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:13RPRPHPVLW0.78350.85511019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B39:11NRPRPHPVL0.73570.8574918
PANK1-ABCC2chr1091404357chr10101606718859HLA-A32:01RPRPHPVLW0.72190.93011019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:17RPRPHPVLW0.71090.61541019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:30RPRPHPVLW0.71090.61541019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C03:67NRPRPHPVL0.70890.9767918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:23RPRPHPVLW0.68560.69881019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:11RPRPHPVLW0.51470.76461019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B57:02RPRPHPVLW0.49830.8621019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C06:06NRPRPHPVL0.39970.994918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:26RPRPHPVLW0.34860.60571019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B59:01RPRPHPVLW0.28380.76461019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C06:02NRPRPHPVL0.23590.9938918
PANK1-ABCC2chr1091404357chr10101606718859HLA-C06:17NRPRPHPVL0.23590.9938918
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:24RPRPHPVLW0.20550.92291019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B55:04RPRPHPVLW0.17860.65031019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:22RPRPHPVLW0.11220.67381019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B82:02RPRPHPVLW0.08460.70161019
PANK1-ABCC2chr1091404357chr10101606718859HLA-A25:01RPRPHPVLW0.05130.85121019
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:01RPRPHPVLW0.05040.63271019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B35:43RPRPHPVLW0.04210.7951019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B51:21RPRPHPVLW0.04140.50981019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:08RPRPHPVLW0.04060.79271019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:11RPRPHPVLW0.04010.81351019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B18:07RPRPHPVLW0.02890.66581019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B67:01RPRPHPVLW0.0190.93721019
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:09RPRPHPVLWK0.98480.78321020
PANK1-ABCC2chr1091404357chr10101606718859HLA-C07:22NRPRPHPVLW0.97050.6309919
PANK1-ABCC2chr1091404357chr10101606718859HLA-A30:01RPRPHPVLWK0.9640.9351020
PANK1-ABCC2chr1091404357chr10101606718859HLA-B15:13NRPRPHPVLW0.82010.7163919
PANK1-ABCC2chr1091404357chr10101606718859HLA-B07:09NRPRPHPVLW0.3820.5224919
PANK1-ABCC2chr1091404357chr10101606718859HLA-B58:06KNRPRPHPVLW0.99940.7034819

Top

Potential FusionNeoAntigen Information of PANK1-ABCC2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PANK1-ABCC2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3083GRKNRPRPHPVLWKPANK1ABCC2chr1091404357chr10101606718859

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PANK1-ABCC2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3083GRKNRPRPHPVLWK-5.3469-5.36
HLA-B14:023BVN3083GRKNRPRPHPVLWK-4.94333-7.21033
HLA-B52:013W393083GRKNRPRPHPVLWK-5.1084-5.1215
HLA-B52:013W393083GRKNRPRPHPVLWK-3.53437-5.80137
HLA-A11:014UQ23083GRKNRPRPHPVLWK-4.15562-6.42262
HLA-A24:025HGA3083GRKNRPRPHPVLWK-7.26935-7.28245
HLA-A24:025HGA3083GRKNRPRPHPVLWK-4.32364-6.59064
HLA-B44:053DX83083GRKNRPRPHPVLWK-6.07067-6.08377
HLA-B44:053DX83083GRKNRPRPHPVLWK-5.84758-8.11458
HLA-A02:016TDR3083GRKNRPRPHPVLWK1000010000

Top

Vaccine Design for the FusionNeoAntigens of PANK1-ABCC2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PANK1-ABCC2chr1091404357chr101016067181018RPRPHPVLACAGGCCGCGACCCCATCCTGTTC
PANK1-ABCC2chr1091404357chr101016067181019RPRPHPVLWACAGGCCGCGACCCCATCCTGTTCTCT
PANK1-ABCC2chr1091404357chr101016067181020RPRPHPVLWKACAGGCCGCGACCCCATCCTGTTCTCTGGA
PANK1-ABCC2chr1091404357chr101016067181119PRPHPVLWGGCCGCGACCCCATCCTGTTCTCT
PANK1-ABCC2chr1091404357chr101016067181221RPHPVLWKPCGCGACCCCATCCTGTTCTCTGGAAGC
PANK1-ABCC2chr1091404357chr10101606718817KNRPRPHPVGAAAGAACAGGCCGCGACCCCATCCTG
PANK1-ABCC2chr1091404357chr10101606718819KNRPRPHPVLWGAAAGAACAGGCCGCGACCCCATCCTGTTCTCT
PANK1-ABCC2chr1091404357chr10101606718917NRPRPHPVAGAACAGGCCGCGACCCCATCCTG
PANK1-ABCC2chr1091404357chr10101606718918NRPRPHPVLAGAACAGGCCGCGACCCCATCCTGTTC
PANK1-ABCC2chr1091404357chr10101606718919NRPRPHPVLWAGAACAGGCCGCGACCCCATCCTGTTCTCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PANK1-ABCC2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADPANK1-ABCC2chr1091404357ENST00000307534chr10101606718ENST00000370449TCGA-KB-A93J-01A

Top

Potential target of CAR-T therapy development for PANK1-ABCC2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PANK1-ABCC2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PANK1-ABCC2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource